News - tabalumab, Anti-Arthritics/Rheumatics

Filter

Popular Filters

Arthritis drug disappointment: will fostamatinib's failure force pharma back to the drawing board?

10-06-2013

Recent news of fostamatinib's latest failure to meet clinical endpoints marks yet another blow to an…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyEli LillyfostamatinibPfizerPharmaceuticalRegulationResearchRigel PharmaceuticalstabalumabXeljanz

Lack of efficacy causes Eli Lilly to drop Ph III RA program for tabalumab

08-02-2013

US drug major Eli Lilly (NYSE: LLY) says that it will discontinue the Phase III rheumatoid arthritis…

Anti-Arthritics/RheumaticsEli LillyPharmaceuticalResearchtabalumab

Eli Lilly drops one tabalumab trial for RA

14-12-2012

US drug major Eli Lilly (NYSE: LLY) says that it will stop one of three Phase III rheumatoid arthritis…

Anti-Arthritics/RheumaticsEli LillyPharmaceuticalResearchtabalumab

Back to top